Princess Maxima Center & University Medical Center Utrecht, Netherlands alexander.eggermont
Verified email at - Homepage
Cited by
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
Final version of 2009 AJCC melanoma staging and classification
CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ...
Journal of clinical oncology 27 (36), 6199, 2009
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ...
Science 350 (6264), 1079-1084, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
New England Journal of Medicine 375 (19), 1845-1855, 2016
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
The lancet oncology 16 (5), 522-530, 2015
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
TNF‐α in cancer treatment: molecular insights, antitumor effects, and clinical utility
R van Horssen, TLM Ten Hagen, AMM Eggermont
The oncologist 11 (4), 397-408, 2006
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
Delivering affordable cancer care in high-income countries
R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ...
The lancet oncology 12 (10), 933-980, 2011
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
AMM Eggermont, S Suciu, M Santinami, A Testori, WHJ Kruit, J Marsden, ...
The Lancet 372 (9633), 117-126, 2008
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable …
A Hauschild, SS Agarwala, U Trefzer, D Hogg, C Robert, P Hersey, ...
J Clin Oncol, Epub ahead of print, PMID 19349552, 2007
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ...
Annals of Oncology 27 (4), 559-574, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ...
Nature reviews Clinical oncology 13 (8), 473, 2016
Improved endpoints for cancer immunotherapy trials
A Hoos, AMM Eggermont, S Janetzki, FS Hodi, R Ibrahim, A Anderson, ...
Journal of the National Cancer Institute 102 (18), 1388-1397, 2010
The system can't perform the operation now. Try again later.
Articles 1–20